Cargando…

Dissemination and evaluation of the ASAS/EULAR recommendations for the management of ankylosing spondylitis: results of a study among 1507 rheumatologists

BACKGROUND: Ten ASAS/EULAR recommendations for the management of ankylosing spondylitis (AS) were published in 2006. OBJECTIVES: (a) To disseminate and (b) to evaluate conceptual agreement with, and (c) application of, these recommendations as well as (d) potential barriers to the application. METHO...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gossec, L, Dougados, M, Phillips, C, Hammoudeh, M, de Vlam, K, Pavelka, K, Pham, T, Braun, J, Sieper, J, Olivieri, I, van der Heijde, D, Collantes, E, Stone, M, Kvien, T K
Formato:	Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2008
Materias:	Extended Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2565578/ https://www.ncbi.nlm.nih.gov/pubmed/18055468 http://dx.doi.org/10.1136/ard.2007.080077

Ejemplares similares

2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis
por: Braun, J, et al.
Publicado: (2011)

Adalimumab effectively reduces the signs and symptoms of active ankylosing spondylitis in patients with total spinal ankylosis
por: van der Heijde, D, et al.
Publicado: (2008)

Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab
por: Visvanathan, S, et al.
Publicado: (2008)

2014 Update of the EULAR standardised operating procedures for EULAR-endorsed recommendations
por: van der Heijde, Désirée, et al.
Publicado: (2015)

Recommendations for the content and conduct of European League Against Rheumatism (EULAR) musculoskeletal ultrasound courses
por: Naredo, E, et al.
Publicado: (2008)

Predicting the outcome of ankylosing spondylitis therapy
por: Vastesaeger, Nathan, et al.
Publicado: (2011)

Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force
por: Smolen, Josef S, et al.
Publicado: (2014)

Early response to adalimumab predicts long-term remission through 5 years of treatment in patients with ankylosing spondylitis
por: Sieper, Joachim, et al.
Publicado: (2011)

Gender difference in ASAS HI among patients with ankylosing spondylitis
por: Chen, Hsin-Hua, et al.
Publicado: (2020)

Scoring radiographic progression in ankylosing spondylitis: should we use the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS) or the Radiographic Ankylosing Spondylitis Spinal Score (RASSS)?
por: Ramiro, Sofia, et al.
Publicado: (2013)

Sick leave and its predictors in ankylosing spondylitis: long-term results from the Outcome in Ankylosing Spondylitis International Study
por: Webers, Casper, et al.
Publicado: (2018)

Translating Improvements with Ixekizumab in Clinical Trial Outcomes into Clinical Practice: ASAS40, Pain, Fatigue, and Sleep in Ankylosing Spondylitis
por: Mease, Philip, et al.
Publicado: (2019)

Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials
por: Sieper, Joachim, et al.
Publicado: (2014)

Differences and similarities between the EULAR/ASAS-EULAR and national recommendations for treatment of patients with psoriatic arthritis and axial spondyloarthritis across Europe
por: Michelsen, Brigitte, et al.
Publicado: (2023)

Efficacy and safety of a novel synergistic drug candidate, CRx-102, in hand osteoarthritis
por: Kvien, T K, et al.
Publicado: (2008)

Person-focused care for young people with rheumatic and musculoskeletal diseases: young rheumatologists' and EULAR Young PARE perspectives
por: Alunno, Alessia, et al.
Publicado: (2017)

Correspondence on "ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update"
por: Braun, Juergen
Publicado: (2023)

The Role of Rheumatologist in Smoking Cessation of Ankylosing Spondylitis Patients: A Single-Center Cross-Sectional Study
por: Kaya, Mehmet Nur, et al.
Publicado: (2023)

Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate
por: Schiff, M, et al.
Publicado: (2008)

Development and validation of an alternative ankylosing spondylitis disease activity score when patient global assessment is unavailable
por: Ortolan, Augusta, et al.
Publicado: (2020)

Level of radiographic damage and radiographic progression are determinants of physical function: a longitudinal analysis of the TEMPO trial
por: van der Heijde, D, et al.
Publicado: (2008)

Fifty years after the discovery of the association of HLA B27 with ankylosing spondylitis
por: Braun, Juergen, et al.
Publicado: (2023)

Validity and reliability of the EULAR instrument RAID.7 as a tool to assess individual domains of impact of disease in rheumatoid arthritis: a cross-sectional study of 671 patients
por: Duarte, Catia, et al.
Publicado: (2021)

Modified stoke ankylosing spondylitis spinal score as an outcome measure to assess the impact of treatment on structural progression in ankylosing spondylitis
por: van der Heijde, Désirée, et al.
Publicado: (2019)

Improving the peer review skills of young rheumatologists and researchers in rheumatology: the EMEUNET Peer Review Mentoring Program
por: Rodríguez-Carrio, Javier, et al.
Publicado: (2018)

The relationship between inflammation and new bone formation in patients with ankylosing spondylitis
por: Baraliakos, Xenofon, et al.
Publicado: (2008)

Is the current ASAS expert definition of a positive family history useful in identifying axial spondyloarthritis? Results from the SPACE and DESIR cohorts
por: Ez-Zaitouni, Zineb, et al.
Publicado: (2017)

Development of EULAR recommendations for the reporting of clinical trial extension studies in rheumatology
por: Buch, Maya H, et al.
Publicado: (2015)

Prevalence of HLA-B27 in Patients with Ankylosing Spondylitis in Qatar
por: Abdelrahman, M. H., et al.
Publicado: (2012)

EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update
por: Gossec, Laure, et al.
Publicado: (2020)

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs
por: Smolen, Josef S, et al.
Publicado: (2010)

Defining cut-off values for disease activity states and improvement scores for patient-reported outcomes: the example of the Rheumatoid Arthritis Impact of Disease (RAID)
por: Dougados, Maxime, et al.
Publicado: (2012)

Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study
por: Landewé, R, et al.
Publicado: (2014)

Physical function, disease activity, and health-related quality-of-life outcomes after 3 years of adalimumab treatment in patients with ankylosing spondylitis
por: van der Heijde, Désirée M, et al.
Publicado: (2009)

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update
por: Smolen, Josef S, et al.
Publicado: (2014)

Ankylosing spondylitis
Publicado: (1980)

Ankylosing spondylitis
por: Edavalath, Mukesh
Publicado: (2010)

Ankylosing Spondylitis
por: Whitfield, A. G. W.
Publicado: (1976)

Ankylosing Spondylitis
por: Ebrahimiadib, Nazanin, et al.
Publicado: (2021)

Efficacy and safety of biological and targeted-synthetic DMARDs: a systematic literature review informing the 2016 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis
por: Sepriano, Alexandre, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_3kb3vkkq47rda4grktia458k5b